When was Remegen founded?

Remegen was founded in 2008 and raised its 1st funding round 12 years after it was founded.

Where is Remegen located?

Remegen is headquartered in Yantai, China.

Who is the current CEO of Remegen?

Jianmin Fang of Remegen. They have also founded 1 company.

How many employees does Remegen have?

As of Apr 30, 2026, the latest employee count at Remegen is 28.

Is Remegen a funded company?

Remegen is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on Mar 16, 2020.

When was the latest funding round of Remegen?

Remegen's latest funding was a $***** PE round on Mar 16, 2020, with participation from 7 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $397M in funding in 2026 to date.

Where does Remegen rank among its competitors?

Remegen ranks 115th amongst 3434 active competitors, of which 1191 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Remegen?

Remegen's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Remegen - 2026 Company Profile, Team, Funding & Competitors

Remegen is a public company based in Yantai (China), founded in 2008 by Jianmin Fang and Weidong Wang. It operates as a Developer of therapies for the treatment of cancer, autoimmune and eye diseases. Remegen has raised $100M in funding from Lilly Asia Ventures. The company has 3434 active competitors, including 1191 funded and 801 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Remegen is a developer of therapies for the treatment of cancer, autoimmune and eye diseases. Its technology is based on antibody and fusion proteins, antibody-drug conjugates (ADCs), and bifunctional antibodies therapies. The platform has developed drug candidate R18 that is the fusion protein for the rheumatoid arthritis treatment.

Website: remegen.com
Email ID: *****@remegen.cn
Phone Number: +86 **********

Key Metrics

Founded Year

2008

Location

Yantai, China

Stage

Public

Total Funding

$100M in 1 round

Latest Funding Round

PE, Mar 16, 2020, $*****

Investors

Lilly Asia Ventures & 11 more

Ranked

115^th among 3434 active competitors

Employee Count

28 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3242 more

Exit Details

Public

View Remegen's full profile

Remegen got listed on Nov 09, 2020.

Click here to take a look at Remegen's IPO in detail

Remegen has raised a total funding of $100M over 1 round. Its latest funding round was a PE round on Mar 16, 2020 for $*****. 7 investors participated in its latest round. Remegen has 12 institutional investors.

Here is the list of recent funding rounds of Remegen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 16, 2020	2375303	PE	3350042	1194886	4243666	1095916

Access funding benchmarks and valuations. Sign up today!

View details of Remegen's funding rounds and investors

The founders of Remegen are Jianmin Fang and Weidong Wang. Jianmin Fang is the CEO of Remegen.

Here are the details of Remegen's key team members:

Jianmin Fang: Co-Founder & CEO of Remegen.
Weidong Wang: Co-Founder of Remegen.

View details of Remegen's Founder profiles and Board Members

Remegen's employee count trend

Remegen has 28 employees as of Apr 26. Here is Remegen's employee count trend over the years:

Uncover Remegen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Remegen include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Remegen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
115th	Remegen 2008, Yantai (China), Public	Developer of therapies for the treatment of cancer, autoimmune and eye diseases	$100M	Orbimed, CDG Capital & 10 others	63/100